Suppr超能文献

单独使用人纯化抗凝血酶或在低分子量肝素或普通肝素存在的情况下,对与人类血凝块相关的凝血酶生成进行药理学调节。

Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.

作者信息

Meddahi S, Bara L, Fessi H, Samama M M

机构信息

Laboratoire de Thrombose Expérimentale, Institut des Cordeliers, Université Pierre et Marie Curie, Paris VI, France.

出版信息

Blood Coagul Fibrinolysis. 2000 Jan;11(1):51-9.

Abstract

Procoagulant activities associated with human clots may contribute to thrombus extension. We investigate the inhibition of clot-associated factor Xa and thrombin activities by purified human antithrombin either alone or as combination with a low molecular weight heparin (enoxaparin) as compared with unfractionated heparin (UFH). The standard clots were prepared by recalcification of frozen platelet-poor human plasma. Clot-associated thrombin was measured on the clot after clot incubation in recalcified buffer or recalcified prothrombin solution. The enzymatic reaction was measured using a specific substrate for thrombin (CBS 3447). The thrombin concentration was determined both on the clots and in the reaction mixtures. In parallel, prothrombin fragment 1.2 and thrombin-antithrombin complexes (TAT) were measured using enzyme-linked immunosorbent assay methods. We demonstrated that in the presence of purified human prothrombin and antithrombin (AT), a partial inhibition of clot associated thrombin activity correlated with an increase of TAT complexes. However, antithrombin was unable to inhibit thrombin generation induced by the clot-associated factor Xa. Enoxaparin (low molecular weight heparin) and UFH did not enhance clot-bound thrombin inhibition induced by AT. We conclude that clot-bound thrombin is accessible to human antithrombin alone. AT is also able to inhibit thrombin generated by factor Xa-associated clot. However, neither a low molecular weight heparin or UFH enhanced the effect of AT alone.

摘要

与人类血凝块相关的促凝血活性可能会导致血栓扩展。我们研究了纯化的人抗凝血酶单独或与低分子量肝素(依诺肝素)联合使用时,与普通肝素(UFH)相比,对血凝块相关的因子Xa和凝血酶活性的抑制作用。标准血凝块通过对冷冻的人少血小板血浆进行重新钙化来制备。在重新钙化的缓冲液或重新钙化的凝血酶原溶液中孵育血凝块后,测量血凝块相关的凝血酶。使用凝血酶的特异性底物(CBS 3447)测量酶促反应。在血凝块和反应混合物中都测定了凝血酶浓度。同时,使用酶联免疫吸附测定方法测量凝血酶原片段1.2和凝血酶-抗凝血酶复合物(TAT)。我们证明,在存在纯化的人凝血酶原和抗凝血酶(AT)的情况下,血凝块相关凝血酶活性的部分抑制与TAT复合物的增加相关。然而,抗凝血酶无法抑制由血凝块相关的因子Xa诱导的凝血酶生成。依诺肝素(低分子量肝素)和UFH并未增强由AT诱导的血凝块结合凝血酶抑制作用。我们得出结论,人抗凝血酶单独即可作用于血凝块结合的凝血酶。AT也能够抑制由因子Xa相关血凝块产生的凝血酶。然而,低分子量肝素或UFH单独都未增强AT的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验